Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Terns Pharmaceuticals's TERN-501?
TERN-501 is a small molecule commercialized by Terns Pharmaceuticals, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH)....